Figure 3.
![Kaplan-Meier estimates by MRD status and MRD conversion among VenR-treated patients in the overall intent-to-treat population. (A) Time to MRD∗ conversion; (B) time from conversion to PD; (C) time from PD to next treatment. ∗MRD was categorized as uMRD (<1 CLL cell per 10 000 leukocytes; MRD value <0.0001 [10–4]) and MRD+ (≥10–4).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/145/23/10.1182_blood.2024025525/2/blood_bld-2024-025525-gr3.jpeg?Expires=1752363183&Signature=qRQAO3EGx4ixsmdt2W1cc~IcnYg3kGgnBWKzgHC0i5mbvLZYEfEQrng76xnubZoMeMnjNsS4XVKWP5D4XDtbsuWiJHkBv7uqxhyPqkZssj7l0MEKuFTlTjC7q7fqQycSD03dwItDMIgwyfLaaFC0E5ZtZDWMwuQFzfynMeAUiGTTrBNvIzo~ULYeg2OStM93n3uDfFE6SLoPC-Ty-kfk75ao~o7BRSQt-3BiPoPxwEWVwsVNEHnpcMY5sJO2xk7VZG6mC4hpL5IgxBv6pZ2zWWCq4GjWijGcFDz3ODVB1NZdU~w2wKMgKzvsSJP9aVyXwA3QE5ej7ZPfUeW7k-ZNmQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Kaplan-Meier estimates by MRD status and MRD conversion among VenR-treated patients in the overall intent-to-treat population. (A) Time to MRD∗ conversion; (B) time from conversion to PD; (C) time from PD to next treatment. ∗MRD was categorized as uMRD (<1 CLL cell per 10 000 leukocytes; MRD value <0.0001 [10–4]) and MRD+ (≥10–4).
